Essen BioScience (part of Sartorius), is a team of engineers and biologists with deep expertise in cell-based assays. They invent, manufacture, supply and support cell-based assay instrumentation, reagents and protocols.
Discover
Related topics
Practical aspects of an imaging study: live in vivo scanning
Nov 11, 2022
In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...
Advances in Leukemia research using shear flow and Bioflux system
May 24, 2022
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
WEBINAR: Recent Advancements In Neurodegenerative Biomarkers
Sep 6, 2021
Recent Advancements in Neurodegenerative Biomarkers: Progress Towards a Diagnostic Blood Test for Alzheimer’s Disease
Recorded Webinar – the basics of Intravital Fluorescence Microscopy
Aug 6, 2021
This is the first of a 4-part series introducing Scintica’s newly formed relationship...
ACCELA webinar recording : IntraVital Microscopy (IVM): In Vivo Live Cell Imaging Platform
Jul 15, 2021
Intravital microscopy can visualize...
Webinar recording: Autofluorescence management - the power of Spectral Flow Cytometry
Jul 15, 2021
One of the key advantages of spectral flow cytometry is its ability to extract sample...
Webinar recording: Super-Resolution imaging of Chromatin organization in health and disease
Jul 9, 2021
Understanding how cells organize the array of components within their membranous confines can not only provide insight...
Jul 8, 2021
NanoView Biosciences has developed...
OMIXYS Educational webinar series: IntraVital Microscopy (IVM): In Vivo Live Cell Imaging Platform
Jun 11, 2021
Intravital microscopy can visualize...
Aug 21, 2017
September 7, 2017, 7 pm CEST
Chia-Wei Li, PhD, The University of Texas M. D. Anderson Cancer Center
Here we reveal PD-L1’s immunosuppression activity is stringently modulated by the spatial restraints between ubiquitination and N-linked glycosylation. We identified GSK3beta as a novel PD-L1 interacting protein capable of inducing phosphorylation dependent proteasome degradation. The essence of PD-L1 N192, N200 and N219 glycosylation suggests it antagonizes GSK3beta binding. In this regard, only non-glycosylated PD-L1 forms a complex with GSK3beta and beta-TrCP. More importantly, activation of GSK3beta-mediated PD-L1 degradation by TKI can reduce membrane PD-L1 expression and thereby enhance anti-tumor immunity. To test T cell-mediated cancer cell killing in vitro, we employed a time lapse microscopy, IncuCyte, to monitor RFP-tagged BT549 cells and activated PBMC interaction over a five day period. Massive cancer cell death was observed in glycosylation deficient cancer cells, suggesting glycosylation of PD-L1 is required for its immunosuppression. Together, our results link ubiquitination and glycosylation pathways with stringent regulation of PD-L1, proposing a new therapeutic strategy to enhance cancer immune therapy efficacy.
Learning objectives:
Related technologies: BioImaging
Brand profile
Essen BioScience (part of Sartorius), is a team of engineers and biologists with deep expertise in cell-based assays. They invent, manufacture, supply and support cell-based assay instrumentation, reagents and protocols.
More info at:
www.essenbioscience.com/